Quincy Attobrah

FDA approves datopotamab deruxtecan-dlnk for first-line metastatic TNBC, improving PFS, OS and response rates vs chemotherapy.

Retifanlimab plus chemotherapy improved survival and response rates in advanced anal cancer with manageable safety in phase 3 findings.

Study findings suggest biologic aging and neighborhood deprivation may shape cognitive benefits from exercise after breast cancer.

A DNP-led RESET program explored ways to improve oncology nurse retention by addressing burnout, resilience and grief through education and support.

Pilot study links gut microbiome patterns to fatigue and pain in melanoma patients receiving immune checkpoint inhibitors.

FDA approved zenocutuzumab-zbco for post-systemic-therapy, NRG1 fusion–positive unresectable/metastatic cholangiocarcinoma, addressing an ultra-rare molecular subset with limited options.

Dr. Mutahar Ahmed of John Theurer Cancer Center highlights nurses’ vital role in bladder cancer care, supporting patients through treatment and recovery

FDA approves vepdegestrant for ER-positive, HER2-negative breast cancer. Learn key efficacy data, safety risks, and nursing care considerations.

Mariefel Vendivil discusses the evolving role of oncology nurses in clinical trials, highlighting patient education, teamwork and emerging technologies.

Phase 3 MagnetisMM-5 trial data in multiple myeloma highlight progression-free survival gains and key safety considerations for oncology nurses.

Paget disease of the breast: key signs, diagnosis, and treatment strategies oncology nurses should know to support early detection and patient care.

Oncology nurses play key role in guiding patients with non-small cell lung cancer on KRAS therapies and emerging options.

FDA accepts Zanidatamab combo sBLA for HER2+ gastroesophageal cancer, showing improved outcomes in HERIZON-GEA-01 trial with priority review underway.

Phase 2 GOG 3039 trial data from SGO 2026 shows abemaciclib and letrozole improved PFS in patients with advanced or recurrent endometrial carcinoma.